Rocket Pharmaceuticals said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder.
A recombinant protein therapy is produced through recombinant DNA technology, which involves inserting the DNA encoding the protein into bacterial or mammalian cells, expressing the protein in these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback